Dicerna Pharmaceuticals Inc (DRNA, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Dicerna Pharmaceuticals Inc is a biopharmaceutical company. It develops ribonucleic acid interference-based pharmaceuticals for treating diseases involving liver, including rare, chronic liver, cardiovascular and viral infections. Dicerna Pharmaceuticals Inc has a market cap of $1.39 billion; its shares were traded at around $19.74 with and P/S ratio of 72.87. GuruFocus has detected 1 severe warning sign with Dicerna Pharmaceuticals Inc. .
For the last quarter Dicerna Pharmaceuticals Inc reported a revenue of $8.04 million, compared with the revenue of $1.55 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $23.9 million, an increase of 287% from last year. For the complete 30-year financial data, please go here.. For the last five years Dicerna Pharmaceuticals Inc had an average revenue decline of 0% a year.
The reported loss per diluted share was $1.76 for the year, compared with the loss per share of $2.87 in the previous year. The Dicerna Pharmaceuticals Inc had an operating margin of -536.25%, compared with the operating margin of -991.26% a year before. The 10-year historical median operating margin of Dicerna Pharmaceuticals Inc is -991.26%. The profitability rank of the company is 1 (out of 10).
At the end of the fiscal year, Dicerna Pharmaceuticals Inc has the cash and cash equivalents of $152.8 million, compared with $54.2 million in the previous year. The long term debt was $20.1 million. Dicerna Pharmaceuticals Inc has a financial strength rank of 5 (out of 10).
At the current stock price of $19.74, Dicerna Pharmaceuticals Inc is traded at 77.8% discount to its historical median P/S valuation band of $88.72. The P/S ratio of the stock is 72.87, while the historical median P/S ratio is 327.38. The stock gained 61.67% during the past 12 months.
Directors and Officers Recent Trades:
- See Remarks Bob D Brown sold 8,185 shares of DRNA stock on 02/10/2020 at the average price of $21. The price of the stock has decreased by 6% since.
- EVP & COO James B Weissman sold 4,360 shares of DRNA stock on 02/03/2020 at the average price of $20.2. The price of the stock has decreased by 2.28% since.
For the complete 20-year historical financial data of DRNA, click here.
